Lower GI 2016

US - Rectal Cancer Consortium (randomized phase II)

MRI-defined T2-3 N0 or T any

N1,2

Nonoperative Management (NOM) for cCR

R E S T A G I N G

RT 50.4 Gy + 5-FU/Cape

FOLFOX/CapeOX 16-18 weeks

R

RT 50.4 Gy + 5-FU/Cape

FOLFOX/CapeOX 16-18 weeks

TME for no cCR

Primary endpoint: 3-year DFS